SCHEMBL1476525

SCHEMBL1476525

O=C(NCCc1ccncc1)c1cc(-c2cccc([N+](=O)[O-])c2)on1

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
FAAH O00519 4/20 0.58
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 1/20 0.52
MAPK1 P28482 1/20 0.52
KMT2A Q03164 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HPGD P15428 2/20 0.51
LMNA P02545 1/20 0.51
HSD17B10 Q99714 1/20 0.51
POLB P06746 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1475551 0.89 ALDH1A1 (0.60) MAPTFAAHALDH1A1SMN1; SMN2MEN1
SCHEMBL1474976 0.89 FAAH (0.61) MAPTFAAHALDH1A1MAPK1HPGD
SCHEMBL15190438 0.84 ALDH1A1 (0.47) MAPTFAAHALDH1A1SMN1; SMN2MEN1
SCHEMBL1474945 0.84 MAPT (0.64) MAPTFAAHALDH1A1SMN1; SMN2MEN1
SCHEMBL1474935 0.84 FAAH (0.81) MAPTFAAHALDH1A1SMN1; SMN2MAPK1
SCHEMBL1476073 0.83 MAPT (0.63) MAPTFAAHALDH1A1SMN1; SMN2HPGD
SCHEMBL1474724 0.83 MAPT (0.63) MAPTFAAHALDH1A1SMN1; SMN2HPGD
SCHEMBL1474441 0.80 MAPT (0.75) MAPTFAAHALDH1A1SMN1; SMN2MEN1
SCHEMBL1474570 0.80 FAAH (0.62) MAPTFAAHALDH1A1SMN1; SMN2HPGD
SCHEMBL1179065 0.79 RAB9A (0.75) ALDH1A1SMN1; SMN2MAPK1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 MAPT 2497/4885FAAH 4712/4885ALDH1A1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.